These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 23919640)

  • 21. Beyond lipid-lowering: effects of statins on endothelial nitric oxide.
    Laufs U
    Eur J Clin Pharmacol; 2003 Mar; 58(11):719-31. PubMed ID: 12634978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiatherosclerotic effects of statins: LDL versus non-LDL effects.
    Selwyn AP
    Curr Atheroscler Rep; 2007 Oct; 9(4):281-5. PubMed ID: 18173955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results.
    Wang CY; Liu PY; Liao JK
    Trends Mol Med; 2008 Jan; 14(1):37-44. PubMed ID: 18068482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pleiotropic effects of statins on the vascular tissue.
    Ikeda U; Shimada K
    Curr Drug Targets Cardiovasc Haematol Disord; 2001 Jun; 1(1):51-8. PubMed ID: 12769664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of the RhoA/Rho-associated, coiled-coil-containing protein kinase-1 pathway is involved in the therapeutic effects of simvastatin on pulmonary arterial hypertension.
    Liu WH; Xu XH; Luo Q; Zhang HL; Wang Y; Xi QY; Zhao ZH; Liu ZH
    Clin Exp Hypertens; 2018; 40(3):224-230. PubMed ID: 29319354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct effects of statins on cells primarily involved in atherosclerosis.
    Chen H; Ikeda U; Shimpo M; Shimada K
    Hypertens Res; 2000 Mar; 23(2):187-92. PubMed ID: 10770267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent developments in the effects of nitric oxide-donating statins on cardiovascular disease through regulation of tetrahydrobiopterin and nitric oxide.
    Ma S; Ma CC
    Vascul Pharmacol; 2014 Nov; 63(2):63-70. PubMed ID: 25139660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statins change the cytokine profile in
    González-Herrera F; Clayton NS; Guzmán-Rivera D; Carrillo I; Castillo C; Catalán M; Anfossi R; Quintero-Pertuz H; Quilaqueo ME; Olea-Azar C; Rivera-Meza M; Kemmerling U; Ridley AJ; Vivar R; Maya JD
    Front Immunol; 2022; 13():1035589. PubMed ID: 36713380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rho-associated coiled-coil-containing kinase 2 deficiency in bone marrow-derived cells leads to increased cholesterol efflux and decreased atherosclerosis.
    Zhou Q; Mei Y; Shoji T; Han X; Kaminski K; Oh GT; Ongusaha PP; Zhang K; Schmitt H; Moser M; Bode C; Liao JK
    Circulation; 2012 Oct; 126(18):2236-47. PubMed ID: 23011471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mevalonate Cascade and Small Rho GTPase in Spinal Cord Injury.
    Eftekharpour E; Nagakannan P; Iqbal MA; Chen QM
    Curr Mol Pharmacol; 2017; 10(2):141-151. PubMed ID: 26758952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance.
    Biasucci LM; Biasillo G; Stefanelli A
    Clin Chem Lab Med; 2010 Dec; 48(12):1685-91. PubMed ID: 20868311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Statins may ameliorate pulmonary hypertension via RhoA/Rho-kinase signaling pathway.
    Xing XQ; Gan Y; Wu SJ; Chen P; Zhou R; Xiang XD
    Med Hypotheses; 2007; 68(5):1108-13. PubMed ID: 17097823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Statins normalize vascular lysyl oxidase down-regulation induced by proatherogenic risk factors.
    Rodríguez C; Alcudia JF; Martínez-González J; Guadall A; Raposo B; Sánchez-Gómez S; Badimon L
    Cardiovasc Res; 2009 Aug; 83(3):595-603. PubMed ID: 19406911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?
    Balakumar P; Kathuria S; Taneja G; Kalra S; Mahadevan N
    J Mol Cell Cardiol; 2012 Jan; 52(1):83-92. PubMed ID: 21968328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pleiotropic effects of statins and related pharmacological experimental approaches.
    Alegret M; Silvestre JS
    Methods Find Exp Clin Pharmacol; 2006 Nov; 28(9):627-56. PubMed ID: 17200729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of Rho-associated kinase in differential regulation by statins of interleukin-1beta- and lipopolysaccharide-mediated nuclear factor kappaB activation and inducible nitric-oxide synthase gene expression in vascular smooth muscle cells.
    Wei CY; Huang KC; Chou YH; Hsieh PF; Lin KH; Lin WW
    Mol Pharmacol; 2006 Mar; 69(3):960-7. PubMed ID: 16317111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pleiotropic effects of statins in atherosclerosis: role on endothelial function, inflammation and immunomodulation.
    Arnaud C; Mach F
    Arch Mal Coeur Vaiss; 2005 Jun; 98(6):661-6. PubMed ID: 16007821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Statins inhibit blastocyst formation by preventing geranylgeranylation.
    Alarcon VB; Marikawa Y
    Mol Hum Reprod; 2016 May; 22(5):350-63. PubMed ID: 26908642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Essential role of TGF-beta/Smad pathway on statin dependent vascular smooth muscle cell regulation.
    Rodríguez-Vita J; Sánchez-Galán E; Santamaría B; Sánchez-López E; Rodrigues-Díez R; Blanco-Colio LM; Egido J; Ortiz A; Ruiz-Ortega M
    PLoS One; 2008; 3(12):e3959. PubMed ID: 19088845
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pleiotropic effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: candidate mechanisms for anti-lipid deposition in blood vessels.
    Kumai T; Matsumoto N; Koitabashi Y; Takeba Y; Oonuma S; Sekine S; Tadokoro M; Kobayashi S
    Curr Med Chem Cardiovasc Hematol Agents; 2005 Jul; 3(3):195-201. PubMed ID: 15974884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.